Search the Newsreel

PBHC5080158 Bond Profile — Key Metrics

This article provides key metrics for the PBHC5080158 bond issued by Pathfinder Bancorp, Inc. The bond has a coupon rate of 9.07%, was issued on December 16, 2020, and matures on October 15, 2030, with an outstanding amount of $25.00 million. Pathfinder Bancorp, Inc. …

CMPS|Compass Pathways PLC|Price:11.260|Chg%:-0.450

This article provides a detailed financial overview of Compass Pathways PLC (CMPS), including its stock performance, key financial figures, analyst ratings, and company information. CMPS is a biotechnology company focused on mental health, specifically developing its COMP360 psilocybin treatment for conditions like treatment-resistant depression. …

Pathfinder Bancorp Inc (MARYLAND) (PBHC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Pathfinder Bancorp Inc (MARYLAND) (PBHC). The company has a current valuation score of 9.78, placing it 6th out of 394 in the Banking Services industry. PBHC's current P/E ratio is -51.15, significantly below its recent high and …

ETFs Investing in UiPath, Inc. Class A Stocks

This article lists various Exchange Traded Funds (ETFs) that hold UiPath, Inc. Class A stocks. It provides a comprehensive table detailing each fund's market value, weight of UiPath stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and …

Could COMPASS Pathways’ (CMPS) Low-Touch Psilocybin Protocol Quietly Redefine Its Competitive Edge in PTSD?

COMPASS Pathways (CMPS) recently released a post-hoc analysis of its COMP360 psilocybin treatment for PTSD, highlighting a low-intervention, standardized support model. This approach, characterized by minimal and largely non-directive support during administration sessions, could enhance the scalability and consistency of COMP360 across various conditions. …

UiPath Stock Just Fell by 15%. Here's Why This Could Be a Great Buying Opportunity.

Key Points OpenAI's launch of OpenAI Presence appears to have been the trigger of the sell-off in UiPath's stock. That new AI solution should not have a major impact on UiPath or its prospects. 10 stocks we like better than UiPath › Announcements from …

Pathkey.Ai (ASX:PKY) Pulls Back 18% Despite Strong 37% Annual Gain — Is the AI Story Intact?

LALPATHLAB: Revenue and profit rose year-over-year, with new acquisitions and a dividend declared

Pathfinder Bancorp (NASDAQ:PBHC) Share Price Crosses Above 50-Day Moving Average - Time to Sell?

UiPath Inc. Class A (PATH) Stock Price | Live Quotes & Charts | NYSE

This article provides live stock quotes and charts for UiPath Inc. Class A (PATH), showing its current price of $10.27 with a daily gain of 0.69%. It notes that there are currently no analyst ratings or earnings information available for the company. The page …

Pathfinder Bancorp (PBHC) Edges Higher Amid Consolidation—Support and Resistance Define Trading Range - ETF Flow

UiPath Inc (PATH) faces 11.0% active-screen hit as automation software weakens

The move matters because it cuts against still-positive recent weekly returns while technical readings remain mixed.

LightPath To Sell China Unit For $4.5 Mln In Shift To Western Manufacturing

(RTTNews) - LightPath Technologies, Inc. (LPTH), a provider of optics and imaging systems, on Thursday said it has agreed to sell its China subsidiary to an entity owned by members of the facility's management team. The U.S. optics company agreed to sell LightPath (Zhenjiang) …

Compass Pathways (CMPS) to Post Quarterly Earnings on Thursday

SkyDrive Enters Business Partnership with Bangkok Airways, SPI and Saha Tokyu to Explore eVTOL Applications in Thailand

Proposed flight routes in the Si Racha District - Fours parties develop roadmap on routes, tickets sales and maintenance hubs in Sri Racha, Bangkok and Ko Samui - TOYOTA, Japan, July 23, 2026--(BUSINESS WIRE)--SkyDrive Inc. ("SkyDrive"), a leading compact eVTOL (*1) aircraft manufacturer based …

LIGHTPATH TECHNOLOGIES INC SEC Filing (Jul 22, 2026)

LightPath Technologies, Inc. (LPTH) has filed Post-Effective Amendments to multiple Form S-3 Registration Statements with the SEC on July 22, 2026. These amendments are intended to withdraw and remove from registration all previously registered shares of Class A common stock and other securities that …

UiPath (PATH) Dips More Than Broader Market: What You Should Know

In the latest trading session, UiPath (PATH) closed at $10.70, marking a -11.13% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.14% for the day. On the other hand, the Dow registered a loss …

What's Going On With the Jump in LightPath Stock Today?

LightPath Technologies (NASDAQ: LPTH) shares are showing strong momentum today, marked by a significant price jump after an extended pullback. This surge appears to be driven by a technical recovery following profit-taking in high-flying small caps, rather than a new fundamental catalyst. Key factors …

PATH or APP: Which AI-driven Tech Stock Should You Bet on?

UiPath PATH and AppLovin Corporation APP are two prominent players leveraging artificial intelligence to transform digital operations. UiPath leads the robotic process automation sector, applying AI to streamline enterprise workflows.AppLovin, on the other hand, operates in the mobile ad tech space, using AI to …

UiPath (NYSE:PATH) Shares Climb 3.5% in the Week as Investors Assess Buyback Calculations

UiPath (NYSE:PATH) shares climbed 3.49% over the past week, with investors noting a significant reduction in Class A shares due to buybacks and increased holdings by a passive investor, amounting to 4.9% of May's Class A shares. The company's Q1 revenue increased by 17% …

Is UiPath's Expanding ARR Reinforcing Its Long-Term Growth Story?

UiPath PATH continues to strengthen its long-term investment case through consistent growth in annualized recurring revenue (ARR), underscoring the resilience of its enterprise automation business and the rising adoption of AI-driven workflow orchestration. PATH's ARR has expanded steadily from $1.46 billion in the fourth …

CMPS stock trades steadily as Compass Pathways expands psilocybin depression program

Compass Pathways' CMPS stock is closely tied to its progress in developing psilocybin therapy for treatment-resistant depression, with investors monitoring trial milestones, cash reserves, and Nasdaq trading performance. The company, a clinical-stage biotech, has no commercial revenue but emphasizes its cash position and R&D …

UiPath, Inc. (PATH) is Attracting Investor Attention: Here is What You Should Know

UiPath (PATH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this enterprise automation software developer have returned +18.3% …

PBHC6303450 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the PBHC6303450 bond, issued by Pathfinder Bancorp, Inc. The bond has a 5.5% coupon rate and the next interest payment is scheduled for July 15, 2026. The article details where to find further bond data such as …

PBHC6303450 Bond Profile — Key Metrics

This article provides key metrics for the PBHC6303450 bond issued by Pathfinder Bancorp, Inc. The bond has a 5.5% coupon rate and matures on October 15, 2030. Pathfinder Bancorp, Inc. is a holding company for Pathfinder Bank, offering various banking services.

LightPath expects customer to switch from Germanium to BlackDiamond materials

LightPath Technologies (NASDAQ: LPTH) has received an $11 million follow-on order for infrared cameras for counter-UAS applications from a major global technology customer. The company expects to transition this customer from Germanium-based optics to its proprietary, domestically produced BlackDiamond™ materials during the program. This …

Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy

Jefferies analysts have expressed support for Compass Pathways' COMP360 treatment model, noting that a new Phase II analysis differentiates its psychological support from traditional psychotherapy. This distinction could lead to fewer regulatory hurdles, with Jefferies estimating a high confidence level for FDA approval of …

COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD

COMPASS Pathways (CMPS) saw its stock drop by 8.6% following the release of 26-week data from its Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression (TRD). While the data showed rapid onset, durable clinical benefit, and a manageable safety profile, reinforcing the …

UiPath Inc (PATH) shows intraday weakness despite active-screen uptick

The split matters because turnover is elevated while the automation-software stock’s trend signal remains inactive.

Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?

COMPASS Pathways (CMPS) recently reported positive 26-week Phase 3 data for its COMP360 psilocybin candidate, showing rapid, durable symptom improvement for treatment-resistant depression with a well-tolerated safety profile. These results, coupled with an ongoing rolling New Drug Application and a more favorable FDA stance …

Does COMPASS Pathways (CMPS) Have Upside Left Above Fair Value?

NEWS Forecast — Price Target — Prediction for 2027

LPTH Forecast — Price Target — Prediction for 2027

Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?

UiPath's (NYSE:PATH) Promising Earnings May Rest On Soft Foundations

Is UiPath (PATH) Poised For A Comeback After Its Recent Earnings Report?